Isotope Production Activities at LBNL and LANSCE-IPF: Development of a new Nb(p,x)90Mo Monitor Reaction and Fe,La(p,x) Production Cross-Section Measurements
Andrew S. Voyles, Shamsu Basunia, Lee A. Bernstein, Eva R. Birnbaum, Jon W. Engle, Stephen A. Graves, Toshihiko Kawano, Amanda M. Lewis, Eric F. Matthews, Jon Morrell, Meiring Nortier, Alexander Springer
Department of Nuclear Engineering – UC Berkeley (Voyles, Bernstein, Lewis, Matthews, Morrell), b Nuclear Science Division – Lawrence Berkeley National Laboratory (Basunia, Bernstein), Isotope Production Facility – Los Alamos National Laboratory (Birnbaum, Nortier), d Department of Medical Physics – University of Wisconsin – Madison (Engle), e Department of Radiation Oncology – University of Iowa (Graves), Theoretical Division – Los Alamos National Laboratory (Kawano), Karlsruhe Institute of Technology (Springer)
Oral Presentation
The co-authors listed herein, and the Nuclear Physics group of the University of Oslo.
We gratefully acknowledge support for this work from the United States Department of Energy, Office of Science via the Isotope Development and Production for Research and Applications subprogram in the Office of Nuclear Physics. This work has been carried out under the auspices of the U.S. Department of Energy by Lawrence Berkeley National Laboratory and the U.S. Nucle-ar Data Program under contract # DE-AC02-05CH11231. This research was performed under appointment to the Rickover Fellowship Program in Nuclear Engineering, sponsored by the Naval Reactors Division of the U.S. Department of En-ergy. Additional support has been provided by the U.S. Nuclear Regulatory Commission. This research used the Savio computational cluster resource provided by the Berkeley Research Computing program at the University of Califor-nia, Berkeley (supported by the UC Berkeley Chancellor, Vice Chancellor for Research, and Chief Information Officer).
The future of nuclear medicine would appear to be the paradigm of personalized medicine — targeted radionuclide therapy to spare healthy tissue, and theranostic medicine, which pairs an imaging isotope with a therapeutic isotope to provide simultaneous, real-time dose delivery and verification, leading to drastic reductions in prescribed patient dose.
Candidate isotopes to meet these needs have been identified based on their chemical and radioactive decay properties. The Bay Area Nuclear Data (BAND) Group is currently leading a series of campaigns to perform targeted, high-priority measurements of thin-target cross sections and thick-target integral yields, as part of a larger campaign to address deficiencies in cross-cutting nuclear data needs. These studies will serve to facilitate the production of pre-clinical quantities of radioactivity for emerging and novel medical radionuclides. This talk will focus on the BAND Group’s recent efforts to measure production cross sections for emerging novel medical radio-nuclides and develop new methods for the monitoring of charged-particle beams. In addition, these experiments provide valuable insight into the challenges and unexpected nuances involved in precision cross-section data measurements.